{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:36:15Z","timestamp":1784115375195,"version":"3.55.0"},"reference-count":68,"publisher":"Georg Thieme Verlag KG","issue":"06","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":163,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Based on my work as a clinical neurologist with more than 50 years of experience in caring for patients with Alzheimer's disease (AD), I focus, in this review article, on the disease's two fundamental aspects for the doctor: diagnosis and treatment. The 1984 diagnostic criteria had been stable for more than a quarter of a century when it was replaced in 2011. Since then, there have been many discoveries, especially of biomarkers that have a heavy impact on the diagnosis of AD. Recently, AD biomarkers have become available in plasma, which certainly will cause a major change in the diagnosis of biological AD, a term that still needs care and information to society before being used in clinical practice. Three monoclonal antibodies against \u03b2-amyloid peptide have also been recently approved, and two of these have shown a small but statistically significant effect on clinical outcome. These monoclonal antibodies have had a greater effect on the reduction of amyloid plaques in the brain assessed by positron emission tomography (PET), and on the concentration of biomarkers in the cerebrospinal fluid (\u03b2-amyloid peptide with 42 amino acids and hyperphosphorylated tau protein) than in the neuropsychological and functional assessments. Even this small clinical effect will be encouraging for the development of new research, particularly helped by the greater ease of diagnosis and monitoring of the evolution of AD pathophysiology with plasma biomarkers. Recently, new diagnostic criteria for AD were presented by the Alzheimer's Association, causing controversy about their use in clinical practice.<\/jats:p>","DOI":"10.1055\/s-0044-1791755","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T01:59:46Z","timestamp":1731376786000},"page":"001-009","source":"Crossref","is-referenced-by-count":2,"title":["Alzheimer's disease: part 2 \u2013 the present"],"prefix":"10.1055","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5721-1525","authenticated-orcid":false,"given":"Ricardo","family":"Nitrini","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"issue":"07","key":"ref1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"G McKhann","year":"1984","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0278-5846(86)90009-6","article-title":"Brain changes in dementia of Alzheimer's type relevant to new imaging diagnostic methods","volume":"10","author":"A Brun","year":"1986","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"10","key":"ref3","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/jnnp.55.10.967","article-title":"Atrophy of medial temporal lobes on MRI in \u201cprobable\u201d Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates","volume":"55","author":"P Scheltens","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"04","key":"ref4","first-page":"548","article-title":"Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains","volume":"42","author":"K Ishii","year":"2001","journal-title":"J Nucl Med"},{"issue":"04","key":"ref5","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Z S Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"ref6","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/gps.1610","article-title":"The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening","volume":"21","author":"E Mioshi","year":"2006","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1590\/S0004-282X2003000300004","article-title":"Brazilian version of the Mattis dementia rating scale: diagnosis of mild dementia in Alzheimer's disease","volume":"61","author":"C S Porto","year":"2003","journal-title":"Arq Neuropsiquiatr"},{"issue":"02","key":"ref8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/WAD.0b013e318191c7dd","article-title":"The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery","volume":"23","author":"S Weintraub","year":"2009","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"04","key":"ref10","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1017\/S1355617704104062","article-title":"Performance of illiterate and literate nondemented elderly subjects in two tests of long-term memory","volume":"10","author":"R Nitrini","year":"2004","journal-title":"J Int Neuropsychol Soc"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome","volume":"56","author":"R C Petersen","year":"1999","journal-title":"Arch Neurol"},{"issue":"07","key":"ref12","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1073\/pnas.89.7.2551","article-title":"Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients","volume":"89","author":"W E Van Nostrand","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"04","key":"ref13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/ana.410380413","article-title":"Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease","volume":"38","author":"R Motter","year":"1995","journal-title":"Ann Neurol"},{"issue":"01","key":"ref14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/s0304-3940(00)01036-3","article-title":"Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization","volume":"285","author":"E Vanmechelen","year":"2000","journal-title":"Neurosci Lett"},{"issue":"01","key":"ref15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1006\/exnr.2000.7501","article-title":"CSF phosphorylated tau protein and mild cognitive impairment: a prospective study","volume":"166","author":"H Arai","year":"2000","journal-title":"Exp Neurol"},{"issue":"03","key":"ref16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"W E Klunk","year":"2004","journal-title":"Ann Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1093\/brain\/awl178","article-title":"Two-year follow-up of amyloid deposition in patients with Alzheimer's disease","volume":"129","author":"H Engler","year":"2006","journal-title":"Brain"},{"issue":"03","key":"ref18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"G M McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awr038","article-title":"18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease","volume":"134","author":"M T Fodero-Tavoletti","year":"2011","journal-title":"Brain"},{"issue":"05","key":"ref20","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1017\/cjn.2014.15","article-title":"Developments in Tau PET Imaging","volume":"41","author":"E R Zimmer","year":"2014","journal-title":"Can J Neurol Sci"},{"issue":"05","key":"ref21","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"C R Jack Jr","year":"2016","journal-title":"Neurology"},{"issue":"04","key":"ref22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"C R Jack Jr","year":"2018","journal-title":"Alzheimers Dement"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer's disease","volume":"554","author":"A Nakamura","year":"2018","journal-title":"Nature"},{"issue":"01","key":"ref24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3233\/ADR-230029","article-title":"Plasma Biomarkers of Alzheimer's Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice","volume":"7","author":"M V Pais","year":"2023","journal-title":"J Alzheimers Dis Rep"},{"issue":"01","key":"ref25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13195-024-01469-w","article-title":"Combining plasma A\u03b2 and p-tau217 improves detection of brain amyloid in non-demented elderly","volume":"16","author":"Y Niimi","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"04","key":"ref26","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests","volume":"30","author":"N R Barth\u00e9lemy","year":"2024","journal-title":"Nat Med"},{"issue":"01","key":"ref27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13024-024-00711-1","article-title":"Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting","volume":"19","author":"X Zeng","year":"2024","journal-title":"Mol Neurodegener"},{"issue":"01","key":"ref28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13195-024-01478-9","article-title":"Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients","volume":"16","author":"A J Mendes","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"ref29","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease","volume":"18","author":"O Hansson","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"06","key":"ref30","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group","volume":"20","author":"B Dubois","year":"2021","journal-title":"Lancet Neurol"},{"issue":"03","key":"ref31","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1590\/S1980-5764-2016DN1003002","article-title":"Subjective cognitive decline: The first clinical manifestation of Alzheimer's disease?","volume":"10","author":"A Studart","year":"2016","journal-title":"Dement Neuropsychol"},{"issue":"08","key":"ref34","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup","volume":"20","author":"C R Jack Jr","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"01","key":"ref35","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1212\/WNL.0000000000009724","article-title":"ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project","volume":"95","author":"J L Ebenau","year":"2020","journal-title":"Neurology"},{"issue":"11","key":"ref36","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","article-title":"Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline","volume":"28","author":"R Ossenkoppele","year":"2022","journal-title":"Nat Med"},{"issue":"04","key":"ref37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1001\/archneur.1976","article-title":"Editorial: The prevalence and malignancy of Alzheimer disease. A major killer","volume":"33","author":"R Katzman","year":"1976","journal-title":"Arch Neurol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"E001","DOI":"10.1590\/1980-5764-dn-2024-e001","article-title":"What is \u201cbiological Alzheimer's disease\u201d?","volume":"18","author":"R Nitrini","year":"2024","journal-title":"Dement Neuropsychol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","article-title":"A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial","volume":"385","author":"T Ngandu","year":"2015","journal-title":"Lancet"},{"issue":"07","key":"ref40","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/alz.12123","article-title":"World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia","volume":"16","author":"M Kivipelto","year":"2020","journal-title":"Alzheimers Dement"},{"issue":"09","key":"ref41","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1002\/alz.13101","article-title":"Latin American Initiative for Lifestyle Intervention to Prevent Cognitive Decline (LatAm-FINGERS): Study design and harmonization","volume":"19","author":"L Crivelli","year":"2023","journal-title":"Alzheimers Dement"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"G Livingston","year":"2020","journal-title":"Lancet"},{"issue":"05","key":"ref43","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1002\/alz.12820","article-title":"Risk factors for dementia in Brazil: Differences by region and race","volume":"19","author":"C K Suemoto","year":"2023","journal-title":"Alzheimers Dement"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","article-title":"Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission","volume":"404","author":"G Livingston","year":"2024","journal-title":"Lancet"},{"issue":"01","key":"ref45","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer's disease","volume":"14","author":"M A DeTure","year":"2019","journal-title":"Mol Neurodegener"},{"issue":"06","key":"ref46","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/bpa.12719","article-title":"Neuropathological lesions in the very old: results from a large Brazilian autopsy study","volume":"29","author":"C K Suemoto","year":"2019","journal-title":"Brain Pathol"},{"issue":"02","key":"ref47","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/archpsyc.63.2.168","article-title":"Role of genes and environments for explaining Alzheimer disease","volume":"63","author":"M Gatz","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"01","key":"ref48","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41583-021-00533-w","article-title":"The probabilistic model of Alzheimer disease: the amyloid hypothesis revised","volume":"23","author":"G B Frisoni","year":"2022","journal-title":"Nat Rev Neurosci"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3389\/fnins.2019.01309","article-title":"Anticholinergic Drugs in Geriatric Psychopharmacology","volume":"13","author":"J L\u00f3pez-\u00c1lvarez","year":"2019","journal-title":"Front Neurosci"},{"issue":"01","key":"ref50","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0197-4580(80)90022-6","article-title":"Aging, memory, and the cholinergic system: a study of dichotic listening","volume":"1","author":"D A Drachman","year":"1980","journal-title":"Neurobiol Aging"},{"issue":"01","key":"ref51","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1101\/lm.69204","article-title":"The cholinergic lesion of Alzheimer's disease: pivotal factor or side show?","volume":"11","author":"M Mesulam","year":"2004","journal-title":"Learn Mem"},{"issue":"20","key":"ref52","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1056\/NEJM198611133152001","article-title":"Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type","volume":"315","author":"W K Summers","year":"1986","journal-title":"N Engl J Med"},{"issue":"20","key":"ref53","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJM198611133152008","article-title":"Cholinergic drugs in Alzheimer's disease","volume":"315","author":"K L Davis","year":"1986","journal-title":"N Engl J Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"108352","DOI":"10.1016\/j.neuropharm.2020.108352","article-title":"Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease","volume":"190","author":"G Marucci","year":"2021","journal-title":"Neuropharmacology"},{"issue":"01","key":"ref55","doi-asserted-by":"publisher","first-page":"12214","DOI":"10.1038\/s41598-022-16476-w","article-title":"Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia","volume":"12","author":"M Zuin","year":"2022","journal-title":"Sci Rep"},{"issue":"17","key":"ref56","doi-asserted-by":"publisher","first-page":"e2220","DOI":"10.1212\/WNL.0000000000011832","article-title":"Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality","volume":"96","author":"H Xu","year":"2021","journal-title":"Neurology"},{"key":"ref57","first-page":"91","article-title":"Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties","volume":"43","author":"J Kornhuber","year":"1994","journal-title":"J Neural Transm Suppl"},{"issue":"03","key":"ref59","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jama.291.3.317","article-title":"Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial","volume":"291","author":"P N Tariot","year":"2004","journal-title":"JAMA"},{"issue":"01","key":"ref60","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s43856-024-00527-6","article-title":"Combined use of Donepezil and Memantine increases the probability of five-year survival of Alzheimer's disease patients","volume":"4","author":"E Yaghmaei","year":"2024","journal-title":"Commun Med (Lond)"},{"issue":"06","key":"ref61","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"D J Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"04","key":"ref62","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/alz.12213","article-title":"Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019","volume":"17","author":"D S Knopman","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"02","key":"ref63","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease","volume":"9","author":"S Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"03","key":"ref65","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3233\/JAD-220262","article-title":"Making the Case for Accelerated Withdrawal of Aducanumab","volume":"87","author":"P Whitehouse","year":"2022","journal-title":"J Alzheimers Dis"},{"issue":"06","key":"ref67","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jama.2023.12548","article-title":"Alzheimer Drug Lecanemab Gains Traditional FDA Approval","volume":"330","author":"E Harris","year":"2023","journal-title":"JAMA"},{"issue":"01","key":"ref68","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer's disease","volume":"16","author":"L S Honig","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"01","key":"ref69","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer's Disease","volume":"388","author":"C H van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"01","key":"ref70","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease","volume":"79","author":"S Salloway","year":"2022","journal-title":"JAMA Neurol"},{"issue":"04","key":"ref71","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1093\/brain\/awad049","article-title":"An anti-amyloid therapy works for Alzheimer's disease: why has it taken so long and what is next?","volume":"146","author":"J Hardy","year":"2023","journal-title":"Brain"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"e20230099","DOI":"10.1590\/1980-5764-DN-2023-0099","article-title":"Anti-amyloid therapies do not slow Alzheimer's disease progression","volume":"17","author":"M Kurkinen","year":"2024","journal-title":"Dement Neuropsychol"},{"issue":"06","key":"ref76","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"J R Sims","year":"2023","journal-title":"JAMA"},{"issue":"02","key":"ref77","doi-asserted-by":"publisher","first-page":"e12465","DOI":"10.1002\/trc2.12465","article-title":"Alzheimer's disease drug development pipeline: 2024","volume":"10","author":"J Cummings","year":"2024","journal-title":"Alzheimers Dement (N Y)"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1791755.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T01:59:49Z","timestamp":1731376789000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1791755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":68,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2024,2,7]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["s00441791755"],"URL":"https:\/\/doi.org\/10.1055\/s-0044-1791755","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}